Tactile Systems Technology Inc Dossier
Qualitative Analysis
Business overview
Tactile Systems Technology, Inc. (doing business as Tactile Medical) is a medical technology company that develops and provides innovative medical devices for the treatment of underserved chronic diseases. The company's proprietary platform, the Flexitouch Plus system, provides a clinically proven, home-based advanced pneumatic compression solution for lymphedema patients. Tactile Medical also offers the Entre Plus and Nimbl systems for lymphedema management, the ACTitouch system for chronic venous insufficiency, and the AffloVest airway clearance vest for chronic respiratory conditions such as bronchiectasis. The company operates primarily through a direct-to-patient model for its lymphedema products and a durable medical equipment (DME) distribution model for its respiratory therapy line.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing on maximizing the productivity of a fully resourced direct sales organization and expanding access to advanced therapies under the National Coverage Determination (NCD).
Expected impact: Sustained double-digit top-line growth across both the lymphedema and airway clearance product lines.
Advancing digital capabilities, including the Kylee patient engagement application and AI-enabled order management platforms, to streamline operations and handle regulatory requirements such as Medicare prior authorizations.
Expected impact: Improved operational agility, reduced administrative friction, and enhanced patient compliance and lifetime value.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of LymphaTech's 3D digital lymphedema measurement platform to transition Tactile Medical from a product-based company to a comprehensive, integrated solutions leader for lymphatic dysfunction.
Financial impact: Upfront cash payment of $6.8 million funded from cash on hand, with potential additional milestone-based contingent consideration. Expected to contribute to 2026 revenue growth.